Title: Influence of Thalidomide on the level of plasma vascular endothelial growth factor and basic fibroblast growth factor in acute leukemia before and after treatment
Abstract:Objective: To observe the clinical effect and the influence of Thalidomide combined with chemotherapy on the level of plasma vascular endothelial growth factor(VEGF) and basic fibroblast growth factor...Objective: To observe the clinical effect and the influence of Thalidomide combined with chemotherapy on the level of plasma vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) in acute leukemia before and after treatment.Methods: 36 cases of acute leukemia patients were randomly divided into experimental group and control group,each 18 cases.Each group was treated with conventional chemotherapy in the standard-dose,meanwhile the experimental group was given Thalidomide 100 mg/d additionally.Before treatment and 8 weeks after treatment,plasma were collected for the detection of VEGF,bFGF content.Plasma VEGF and bFGF in 15 cases of healthy people were detected as the standard control value,compared with Leukemia patients.Results: The effective rate of experimental group and control group were 88.9%(16/18),77.8%(14/18) respectively,the difference was statistically significant(χ2=4.10,P0.05).The level of plasma VEGF and bFGF of experimental group and control group before and after treatment were[(389.78±249.94)ng/L,(211.74±36.72)ng/L],[(318.54±125.78)ng/L,(288.02±31.77)ng/L],[(2.43±0.27)μg/L,(2.09±0.17)μg/L],[(2.41±0.33)μg/L,(2.11±0.31)μg/L],the difference were significant compared with healthy group[(132.91±26.66)ng/L,(1.83±0.44)μg/L](P0.05);the level of plasma VEGF of experimental group after treatment was significantly different compared with control group(t=2.79,P0.05),but the level of plasma bFGF shows no difference between experimental group and control group(t=1.28,P0.05).Conclusion: Thalidomide combined with chemotherapy can improve the remission rate in patients with acute leukemia,and its mechanism may be conduced through inhibiting the plasma levels of VEGF and its receptor expression to active anti-proliferative,then take effect on anti-leukemia effection.Read More
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot